Zobrazeno 1 - 10
of 83
pro vyhledávání: '"John A. Hadfield"'
Publikováno v:
Molecules, Vol 5, Iss 1, Pp 82-88 (2000)
A short, high-yielding synthesis of the antitumour agent irisquinone (1) is described. The key steps are the palladium catalysed coupling reaction of dec-9-yn-1-ol with iodide (2) to form alkyne (3) and the Fremy’s salt oxidation of phen
Externí odkaz:
https://doaj.org/article/ec793b4f6e2240adbdc4f818f1d9ead5
Autor:
Natalie G. Barnes, Patricia A. Ragazzon, Nadia Charafi, Amjed A. Ahmed Mal Ullah, John A. Hadfield
Publikováno v:
ChemistrySelect. 6:7082-7086
Combretastatin A‐4 (CA4) is a potent anti‐mitotic and vascular disrupting agent. Organic chemists have been working to optimize the synthesis of CA4 for the past 3 decades, with methods requiring hazardous solvents and harsh reaction conditions.
Autor:
Patricia A. Ragazzon, Nicholas Omonga, Abby Ragazzon-Smith, Hesham Ghanbour, Zakia Zia, John A. Hadfield, H.A. Foster
In this paper, novel synthetic methods, including microwave O-alkylation, were used to produce several chrysin derivatives. These compounds were purified, characterised and tested on different cell lines and bacterial strains. From this family, 7-(2,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::499c4f9055c2e41e2d89c26fca1ef404
https://usir.salford.ac.uk/id/eprint/62485/2/17475198211057467.pdf
https://usir.salford.ac.uk/id/eprint/62485/2/17475198211057467.pdf
Autor:
Timothy W. Wallace, John A. Hadfield, Steven B. Rossington, Kaye J. Williams, Steven D. Shnyder
Publikováno v:
Rossington, S, Hadfield, J, Shnyder, S D, Wallace, T & Williams, K 2017, ' Tubulin-binding dibenz[c,e]oxepines : Part 2. Structural variation and biological evaluation as tumour vasculature disrupting agents ', Bioorganic and Medicinal Chemistry, vol. 25, no. 5, pp. 1630-1642 . https://doi.org/10.1016/j.bmc.2017.01.027
5,7-Dihydro-3,9,10,11-tetramethoxybenz[c,e]oxepin-4-ol 1, prepared from a dibenzyl ether precursor via Pd-catalysed intramolecular direct arylation, possesses broad-spectrum in vitro cytotoxicity towards various tumour cell lines, and induces vascula
Autor:
John A. Hadfield, Anthony W. Parker, Amjed A. Ahmed Mal Ullah, Patricia A. Ragazzon, Natalie G. Barnes
Publikováno v:
Bioorganic & Medicinal Chemistry. 28:115684
A series of combretastatin derivatives were designed and synthesised by a two-step stereoselective synthesis by use of Wittig olefination followed by Suzuki cross-coupling. Interestingly, all new compounds (2a-2i) showed potent cell-based antiprolife
In this study, we describe a microwave-based click chemistry method used to prepare a family of novel bis-flavone dimers. The substituted 7-hydroxy and 4’-hydroxy flavonoids were linked through a triazole ring. The compounds were easily synthesized
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e30c252edc6fc228d28900fc76d12ab
Autor:
Stanley W. Botchway, Kathrin M. Scherer, Anthony W. Parker, John A. Hadfield, Michael Towrie, Roger H. Bisby, Greg M. Greetham
Publikováno v:
Biomedical Spectroscopy and Imaging. 3:211-218
Fluorescence lifetime imaging has been used to observe the real-time uptake in live mammalian cells of a combretastatin-type drug analogue that is a substituted stilbene with a cyano group at the bridging olefinic bond. Fluorescence spectra in a rang
Publikováno v:
ChemInform. 47
The newly developed robust system for the 1,3-oxidative transposition of readily accessible aromatic allylic alcohols affords exclusively (E)-cinnamaldehydes in high yields.
We report the catalytic chromium-mediated oxidation of secondary allylic alcohols to give α,β-unsaturated aldehydes with exclusive (E)-stereoselectivity. This facile procedure employs catalytic PCC (5 mol%) and periodic acid (H5IO6) as a co-oxidant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddc1a417f069f2704031fb1d379e0685
Publikováno v:
Journal of Labelled Compounds and Radiopharmaceuticals. 55:303-306
Zybrestat (combretastatin A-4 disodium diphosphate) is currently in clinical trials as an antivascular anticancer agent. A similar fluorinated agent has shown promise as an antivascular agent and a radiolabelled version would enable further understan